查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016884

經導管肺動脈瓣膜市場：按瓣膜類型、應用和最終用戶分類－2026-2032年全球市場預測

Transcatheter Pulmonary Valve Market by Valve Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，經導管肺動脈瓣膜市場價值將達到 7,620 萬美元，到 2026 年將成長至 8,559 萬美元，到 2032 年將達到 1.422 億美元，年複合成長率為 9.32%。

主要市場統計數據
基準年 2025 7620萬美元
預計年份：2026年 8559萬美元
預測年份 2032 1.422億美元
複合年成長率 (%) 9.32%

全面介紹經導管肺動脈瓣治療，重點在於臨床進展、手術的廣泛應用以及對相關人員的策略意義。

經導管肺動脈瓣置換術已從一項實驗性干預發展成為一項臨床有效的治療選擇，滿足了先天性和後天性右心室流出道功能障礙患者的重大未滿足醫療需求。經皮瓣膜置換系統的引入使臨床醫生能夠為先天性疾病兒童和成人患者提供一種微創的替代開胸手術方案，從而減少手術全期併發症並縮短康復時間。技術的改進、影像技術的進步以及對患者選擇標準的更深入理解，共同提升了治療效果，並擴大了經導管肺動脈瓣置換術的臨床適應症。

對正在重塑肺動脈瓣膜治療和醫療保健服務策略的突破性技術、臨床和營運變革進行權威性綜述。

肺動脈瓣膜治療領域正經歷著一場變革性的轉變，這主要得益於技術、臨床和操作等多方面趨勢的共同推動。瓣膜設計的進步，包括改進的徑向力分佈、組織工程以及輸送系統柔軟性，正在擴大瓣膜的解剖學適用範圍，並降低手術入路帶來的挑戰。先進的影像技術和整合式引導平台能夠實現瓣膜在複雜的右心室流出道內的精準定位和尺寸選擇，從而降低併發症率，並增強臨床醫生在以往風險較高的解剖結構中進行手術的信心。

對 2025 年美國關稅變化將如何重塑心臟設備產業的供應鏈、採購經濟和戰略製造決策進行清晰分析。

美國將於2025年實施的新關稅措施，為醫療設備製造商和醫療服務提供者提供了重新評估其供應鏈、採購和定價策略的具體觀點。對進口零件和組裝設備的關稅正在影響採購經濟，迫使製造商探索本地生產、近岸外包以及其他替代採購方式，以維持利潤率並為醫院採購商提供具有競爭力的價格。這些貿易保護主義措施可能會增加依賴全球供應鏈網路的組織的前置作業時間和交易成本，進一步凸顯了多元化採購和庫存緩衝的必要性。

我們從策略角度分析醫療設備、臨床環境和最終用戶的細分，以確定產品功能和病患需求的交匯點，從而塑造商業性和臨床路徑。

詳細的市場細分框架揭示了臨床需求、產品差異化和終端用戶行為如何相互作用，從而影響市場策略。根據瓣膜類型，市場主要分為兩種器械類型：球囊擴張型式和自擴張式。球囊擴張型瓣膜包括成熟的平台，例如 Melody 瓣膜和 Sapien 經導管瓣膜，這些瓣膜已在特定尺寸和導管解剖結構中展現出效用。自擴張式瓣膜則以 Harmony 經導管肺動脈瓣膜和 Venus P 瓣膜等技術為代表，這些技術具有良好的適應性和徑向適應性，適用於更寬且通常不規則的右心室流出道。這些瓣膜類型之間的技術權衡會影響各醫療機構的臨床選擇標準、庫存管理和訓練需求。

簡要的區域概述，比較主要全球區域的採用趨勢、法規環境和商業化路徑。

區域趨勢在塑造市場准入、監管路徑和商業性實施方面發揮核心作用。在美洲，成熟的高績效醫療中心和完善的介入性心臟病學生態系統，以及強大的臨床網路和完善的醫療保險報銷機制，為先進經導管肺動脈瓣膜解決方案的早期應用創造了有利環境。該地區的高手術量、集中的專業技術和活躍的臨床研究群體，為市場准入和擴張提供了有力支持，這些優勢能夠產生上市後的安全性和療效數據。

對塑造肺動脈瓣膜治療領域公司差異化的競爭定位、合作策略和創新重點領域進行了清晰的概述。

經導管肺動脈瓣膜市場的競爭格局既有成熟的循環系統製造商，也有靈活敏捷、專注於創新的創新企業。主要企業優先考慮一種平衡的策略，將器材研發、臨床證據產生和醫療專業人員培訓相結合。器械製造商與先進影像公司之間的合作日益普遍，從而能夠實現更可靠的術前規劃和術中指導。與契約製造製造商和材料科學公司的策略合作也增強了生產的擴充性和組件品管。

為臨床、製造和商業領域的領導者提供實用建議，以加快部署速度，確保供應彈性，並展現差異化的臨床價值。

產業領導者應採取積極主動的策略，協調臨床、商業和營運方面的優先事項，以實現經導管肺動脈瓣膜治療的長期價值。應投資於產生嚴謹的上市後證據，包括基於註冊研究的結果和真實世界績效指標，並為保險公司和轉診機構建立引人入勝的臨床案例。將這種與臨床數據的互動與模組化訓練計畫和使用模擬技術的指導醫師訓練相結合，可以在確保病人安全和手術結果一致性的同時，加速該技術的推廣應用。

透明、多方面的研究途徑，結合臨床訪談、監管審查、供應鏈分析和資料三角驗證，確保獲得可靠、可操作的見解。

本報告的研究結合了質性研究、嚴謹的第二手資料整合以及結構化資料檢驗。主要調查方法包括對介入性心臟病專家、先天性心臟疾病專家、採購經理和行業高管進行深度訪談，以獲取關於器械選擇、手術流程和推廣障礙的第一手資訊。除訪談外，還對同行評審的臨床文獻、監管核准、臨床註冊摘要和器械特定安全資訊進行了結構化審查，以確保與最新的臨床證據和安全訊號保持一致。

簡潔扼要的結論強調，臨床證據、供應彈性和策略商業化是永續推廣和對病人產生影響的先決條件。

經導管肺動脈瓣膜治療正處於轉折點，只有透過技術創新、臨床證據和策略商業化三者之間的和諧平衡，才能實現患者的持續獲益並確立治療方法。瓣膜設計的改進、先進的影像技術以及不斷發展的治療模式正在拓展經皮肺動脈瓣置換術的臨床應用潛力。然而，供應鏈的韌性、價格壓力以及對可靠真實世界數據（REW）的需求等營運挑戰，仍然是影響治療方法普及率和公平性的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 經導管肺動脈瓣膜類型

  • 球囊擴張型閥
    • 旋律閥
    • Sapien經導管瓣膜
  • 自膨脹閥
    • Harmony經導管肺動脈瓣膜
    • 金星P瓣膜

第9章 經導管肺動脈瓣膜市場：依應用領域分類

  • 複雜病變
  • 肺動脈逆流
  • 肺動脈狹窄

第10章 經導管肺動脈瓣膜市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第11章 經導管肺動脈瓣膜市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 經導管肺動脈瓣膜市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 經導管肺動脈瓣膜市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國經導管肺動脈瓣膜市場

第15章：中國經導管肺動脈瓣膜市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Braile Biomedica
  • Jude Medical Inc
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Lifetech Scientific Corporation
  • LivaNova Plc
  • Medtronic plc
  • MicroPort Scientific Corporation
  • TaeWoong Medical Industrial Co., Ltd.
  • Umbra Valve Technologies BV
  • Venus MedTech（Hangzhou）Co., Ltd.
  • Xeltis SA
Product Code: MRR-03168519576D

The Transcatheter Pulmonary Valve Market was valued at USD 76.20 million in 2025 and is projected to grow to USD 85.59 million in 2026, with a CAGR of 9.32%, reaching USD 142.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 76.20 million
Estimated Year [2026] USD 85.59 million
Forecast Year [2032] USD 142.20 million
CAGR (%) 9.32%

A comprehensive introduction to transcatheter pulmonary valve therapy highlighting clinical evolution, procedural adoption, and strategic implications for stakeholders

Transcatheter pulmonary valve therapy has transitioned from an experimental intervention into a clinically viable option that addresses significant unmet needs among patients with congenital and acquired right ventricular outflow tract dysfunction. The introduction of percutaneous valve systems has enabled clinicians to offer less invasive alternatives to repeat open-heart surgery, reducing perioperative morbidity and shortening recovery pathways for both pediatric and adult congenital populations. Procedural refinements, imaging advances, and a deeper understanding of patient selection criteria have collectively strengthened outcomes and expanded the clinical indications for catheter-based pulmonary valve replacement.

Clinical practice now emphasizes heart-team collaboration that integrates congenital cardiologists, interventionalists, cardiac surgeons, and advanced imaging specialists. This multidisciplinary approach optimizes device selection, access strategy, and post-procedural surveillance. As operators accumulate procedural experience and centers codify pathways for patient follow-up, safety profiles have improved while the threshold for treating symptomatic and asymptomatic lesions has evolved. Regulatory clearances and real-world registry data have further legitimized transcatheter pulmonary valve interventions, fostering broader adoption across tertiary referral centers and select ambulatory surgical settings.

From a strategic perspective, device manufacturers, health systems, and clinical investigators are positioned to translate technical advances into scalable care models. The pathway forward requires coordinated investments in training, post-market evidence generation, and supply chain resilience to ensure equitable access and consistent procedural performance across geographies and provider types.

An authoritative synthesis of the transformative technological, clinical, and operational shifts reshaping pulmonary valve therapy and provider strategy

The landscape for pulmonary valve therapies is undergoing transformative shifts driven by converging technological, clinical, and operational dynamics. Advances in valve design, including improvements in radial force profiles, tissue engineering, and delivery-system flexibility, are expanding anatomical applicability and reducing access-related challenges. Enhanced imaging modalities and fusion-guidance platforms enable precise positioning and sizing in complex right ventricular outflow tracts, lowering complication rates and expanding operator confidence in anatomies previously deemed high risk.

Concurrently, a shift in clinical paradigms has emerged as long-term valve durability and patient quality of life become central endpoints. Innovations in device retrievability and modular approaches support staged procedures and tailored therapies for diverse patient cohorts. Regulatory ecosystems are adapting to hybrid evidence models that combine randomized data with high-quality registries, accelerating conditional approvals in regions where unmet need is highest. Reimbursement conversations are likewise evolving, with payers increasingly attentive to value-based metrics such as reduced readmissions, shorter length of stay, and long-term functional improvement.

Operationally, centers of excellence are forming to concentrate expertise and streamline patient pathways, while partnerships between device developers and imaging firms are integrating predictive planning tools. As a result, the competitive landscape is shifting from single-product strategies to integrated solutions that bundle devices, imaging protocols, and clinical training, thereby redefining what it means to deliver high-value transcatheter pulmonary care.

A clear analysis of how the 2025 United States tariff changes are reshaping supply chains, procurement economics, and strategic manufacturing decisions in cardiac device sectors

The implementation of new tariff measures in the United States in 2025 has introduced a tangible lens through which device manufacturers and health providers are re-evaluating supply chain, procurement, and pricing strategies. Tariffs on imported components and assembled devices affect procurement economics, prompting manufacturers to assess localized production, nearshoring options, and alternative sourcing to preserve margin and maintain competitive pricing for hospital purchasers. These protective trade measures can increase lead times and transactional costs for organizations reliant on global supply networks, reinforcing the need for multi-sourcing and inventory buffers.

Clinical programs and hospital purchasers face the prospect of negotiating revised contract terms that account for import-related surcharges and potential variability in device availability. Health systems must balance the imperative of cost containment with clinical imperatives that prioritize patient outcomes; this often necessitates transparent dialogues between clinical leaders and procurement teams to align on acceptable trade-offs and priority access for high-risk patients. In parallel, manufacturers are accelerating efforts to diversify component suppliers, qualify domestic vendors, and invest in automated manufacturing to offset tariff-driven cost pressures.

Policy responses and procurement strategies will ultimately determine the extent to which tariffs alter device adoption trajectories. Stakeholders that proactively model tariff sensitivities, secure contingency manufacturing capacity, and communicate clinical value compellingly to payers and health system buyers will most effectively mitigate the operational disruptions introduced in 2025. This adaptive posture reduces risk to patients and preserves momentum for innovation and broader clinical adoption.

A strategic breakdown of device, clinical, and end-user segmentation revealing where product features and patient needs intersect to shape commercial and clinical pathways

A granular segmentation framework illuminates where clinical demand, product differentiation, and end-user behavior intersect to shape strategy. Based on valve type, the landscape is characterized by two dominant device approaches: balloon expandable designs and self-expanding systems. Balloon expandable valves include well-established platforms such as the Melody valve and the Sapien transcatheter valve, which have proven utility in specific valve sizes and conduit anatomies. Self-expanding systems are represented by technologies like the Harmony transcatheter pulmonary valve and the Venus P-Valve, which offer conformability and radial adaptation suited to broader and often irregular right ventricular outflow tracts. The technical trade-offs between these valve types inform clinical selection criteria, inventory management, and training requirements across centers.

Application-based segmentation further refines clinical pathways and evidence needs. Patient presentations span combined lesions, pulmonary regurgitation, and pulmonary stenosis, each with distinct hemodynamic considerations and procedural planning imperatives. Devices compatible with mixed pathology must demonstrate versatility in sealing, anchoring, and hemodynamic performance, while those intended primarily for stenosis or regurgitation can optimize for low-profile delivery or enhanced radial support, respectively. End-user segmentation underscores where adoption manifests operationally: ambulatory surgical centers, cardiac centers, and hospitals each have unique infrastructure, case mix, and purchasing models. Ambulatory surgical centers may prioritize throughput and same-day discharge protocols, cardiac centers focus on complex cases and multidisciplinary pathways, and hospitals balance acute care capacity with broader inpatient capabilities.

Understanding how valve type, clinical application, and end-user environment interact enables manufacturers and providers to align product portfolios, training programs, and commercialization plans with the practical realities of device deployment and outcomes monitoring.

A concise regional intelligence overview that contrasts adoption dynamics, regulatory environments, and commercialization pathways across key global territories

Regional dynamics play a central role in shaping access, regulatory pathways, and commercial execution. In the Americas, established centers of excellence and a mature interventional cardiology ecosystem create a favorable environment for early adoption of advanced transcatheter pulmonary solutions, supported by robust clinical networks and well-developed reimbursement frameworks. Market entry and scale-up efforts in this region benefit from high procedural volumes, concentrated specialist expertise, and active clinical research communities that generate post-market safety and performance data.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory diversity, variable reimbursement pathways, and disparate infrastructure influence adoption rates. Western European markets typically demonstrate rapid uptake when clinical evidence supports improved outcomes, whereas emerging markets in the broader EMR and African corridors prioritize cost-effective solutions and resilient supply chains. Strategic partners in these geographies often require tailored pricing, capacity-building programs, and local evidence generation to facilitate uptake.

Asia-Pacific exhibits accelerated investment in congenital and structural heart disease programs alongside a strategic emphasis on domestic manufacturing and innovation hubs. Several countries in this region are scaling specialized cardiac centers and driving localized clinical registries that inform device adaptation for population-specific anatomies. Cross-border collaboration and technology transfer initiatives are increasingly common as manufacturers navigate regulatory pathways and local clinical expectations.

An incisive overview of competitive positioning, alliance strategies, and innovation focus areas shaping company-level differentiation in pulmonary valve therapies

The competitive environment in transcatheter pulmonary valves reflects a mix of established cardiovascular device manufacturers and agile specialized innovators. Leading organizations prioritize a balanced approach that couples device engineering with clinical evidence generation and provider education. Partnerships between device makers and advanced imaging firms are becoming commonplace, enabling more reliable pre-procedure planning and intra-procedural guidance. Strategic collaborations with contract manufacturers and material science firms also enhance manufacturing scalability and component quality control.

Innovation pipelines emphasize durability, deliverability, and adaptability to challenging anatomies, with an increasing number of entrants exploring tissue treatments and anti-calcification technologies to extend valve longevity. Commercial strategies focus on bundled service offerings that include proctoring, simulation training, and outcomes support to reduce the learning curve for new adopters. In parallel, some companies are pursuing targeted geographic expansion through local distributors and clinical partnerships, while others invest in direct-market presence where regulatory and reimbursement conditions favor premium positioning.

Mergers, acquisitions, and licensing agreements continue to be strategic levers for achieving category leadership, particularly where complementary imaging, supply chain, or reimbursement expertise can be integrated. Organizations that align robust clinical programs with scalable manufacturing and clear value messaging are best positioned to capture sustained clinical traction and institutional adoption.

Actionable recommendations for clinical, manufacturing, and commercial leaders to accelerate adoption, secure supply resilience, and demonstrate differentiated clinical value

Industry leaders should pursue a proactive strategy that aligns clinical, commercial, and operational priorities to capture long-term value in transcatheter pulmonary valve care. Invest in rigorous post-market evidence generation that includes registry-based outcomes and real-world performance metrics to build a compelling clinical narrative for payers and referral centers. Combine these clinical data efforts with modular training programs and simulation-based proctoring to accelerate adoption while maintaining patient safety and consistent procedural outcomes.

From an operational standpoint, diversify component sourcing and pursue nearshoring where feasible to mitigate tariff exposure and ensure continuity of supply. Engage early with regulatory bodies to clarify pathways for incremental device enhancements and to design adaptive evidence plans that leverage both prospective cohorts and pragmatic registry data. On the commercial front, craft value propositions tailored to end-user segments: emphasize throughput and cost-efficiency for ambulatory surgical facilities, advanced case support and multidisciplinary partnerships for cardiac centers, and comprehensive perioperative care bundles for hospitals.

Finally, pursue strategic collaborations with imaging and digital-health providers to deliver integrated planning tools that reduce procedural variability. Prioritize transparent pricing models and outcomes-linked contracting to align incentives with health systems and payers, thereby supporting broader access while protecting margin and ensuring sustainable growth.

A transparent, multi-method research approach combining clinical interviews, regulatory review, supply-chain analysis, and data triangulation to ensure robust, actionable insights

The research underpinning this report blends primary qualitative engagement with rigorous secondary synthesis and structured data validation. Primary methods included in-depth interviews with interventional cardiologists, congenital heart surgeons, procurement leaders, and industry executives to capture experiential insights on device selection, procedural workflows, and adoption barriers. These conversations were complemented by structured reviews of peer-reviewed clinical literature, regulatory approvals, clinical registry summaries, and device-specific safety communications to ensure alignment with the latest clinical evidence and safety signals.

Data triangulation was applied to reconcile discrepancies between field interviews, clinical reports, and public regulatory documentation, with a focus on reproducibility and source transparency. Manufacturing and supply-chain assessments utilized component mapping, supplier interviews, and publicly available trade data to identify critical nodes of risk and potential mitigation pathways. The analytical framework incorporated thematic coding of qualitative input, scenario analysis for policy and tariff impacts, and comparative device feature matrices to surface differentiators.

Quality assurance included multi-level peer review by clinical and market analysts, verification of primary source citations, and sensitivity checks to ensure conclusions remain robust given variations in regional practice patterns and regulatory timelines. Limitations are acknowledged, including variability in clinical reporting standards across registries and evolving policy environments that may alter procurement and reimbursement dynamics over time.

A concise conclusion emphasizing the alignment of clinical evidence, supply resilience, and strategic commercialization as prerequisites for sustainable adoption and patient impact

Transcatheter pulmonary valve therapy stands at an inflection point where technical innovation, clinical evidence, and strategic commercialization must align to achieve durable patient benefit and sustainable adoption. The confluence of improved valve designs, advanced imaging, and evolving treatment paradigms has expanded the clinical promise of percutaneous pulmonary valve replacement. However, operational challenges such as supply-chain resilience, tariff pressures, and the need for convincing real-world evidence remain critical determinants of the pace and equity of adoption.

For stakeholders crafting strategy in this space, the imperative is clear: invest in durable clinical evidence, secure diversified manufacturing footprints, and tailor commercialization approaches to the specific needs of ambulatory centers, cardiac specialty programs, and hospital systems. Organizations that integrate these elements with flexible pricing frameworks and comprehensive training will be best placed to convert clinical promise into consistent patient access and long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Pulmonary Valve Market, by Valve Type

  • 8.1. Balloon Expandable Valve
    • 8.1.1. Melody Valve
    • 8.1.2. Sapien Transcatheter Valve
  • 8.2. Self Expanding Valve
    • 8.2.1. Harmony Transcatheter Pulmonary Valve
    • 8.2.2. Venus P-Valve

9. Transcatheter Pulmonary Valve Market, by Application

  • 9.1. Combined Lesions
  • 9.2. Pulmonary Regurgitation
  • 9.3. Pulmonary Stenosis

10. Transcatheter Pulmonary Valve Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Transcatheter Pulmonary Valve Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Transcatheter Pulmonary Valve Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Transcatheter Pulmonary Valve Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Transcatheter Pulmonary Valve Market

15. China Transcatheter Pulmonary Valve Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Braile Biomedica
  • 16.6. Jude Medical Inc
  • 16.7. Lepu Medical Technology (Beijing) Co., Ltd.
  • 16.8. Lifetech Scientific Corporation
  • 16.9. LivaNova Plc
  • 16.10. Medtronic plc
  • 16.11. MicroPort Scientific Corporation
  • 16.12. TaeWoong Medical Industrial Co., Ltd.
  • 16.13. Umbra Valve Technologies B.V.
  • 16.14. Venus MedTech (Hangzhou) Co., Ltd.
  • 16.15. Xeltis SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)